Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Outcome of pancreas transplants from 1966 to 2000

Pancreas transplant patient and graft survival rates have significantly improved over time as surgical techniques and immunosuppressive protocols have evolved, according to research published in April's Annals of Surgery.

News image

fiogf49gjkf04

A team from Minneapolis, Minnesota, USA, determined outcome in diabetic pancreas transplant recipients, according to risk factors and the surgical techniques and immunosuppressive protocols that evolved during a 33-year period at a single institution.

Clinical pancreas transplantation began at the University of Minnesota in 1966, initially with a high failure rate, but outcome improved in parallel with other organ transplants.

The authors retrospectively analyzed the factors associated with the increased success rate of pancreas transplants.

The surgeons performed 1,194 pancreas transplants (111 from living donors; 191 re-transplants) between 1966 and 2000. Of these, 498 were simultaneous pancreas-kidney (SPK) and 1 was a simultaneous pancreas-liver transplant. 404 were pancreas after kidney (PAK) transplants; and 291 were pancreas transplants alone (PTA).

The analyses were divided into five eras, depending on the type of immunosuppression and surgical technique used within the time periods: Era 0 (1966 to 1973), historical; Era 1 (1978 to 1986); Era 2 (1986-1994); Era 3 (1994-1998); and Era 4 (1998-2000).

In Era 1 patients underwent solitary (PAK and PTA) transplants involving multiple duct management techniques, and received cyclosporine for immunosuppression.

In Era 2, all varieties of pancreatic transplantation were performed (SPK, PAK, and PTA) with bladder drainage for graft duct management. Cyclosporine, azathioprine, and prednisone were used for immunosuppression.

In Era 3, tacrolimus and mycophenolate mofetil replaced the standard immunosuppressive regime of the previous era.

The surgical technique of Era 4 was primarily enteric drainage for SPK transplants. Daclizumab was used for induction immunosuppression; pre-transplant immunosuppression was used in candidates awaiting PTA.

Pancreas transplant should be an option at all stages of diabetes.
Annals of Surgery

One-year patient and graft survival rates were calculated for each category and era.

The patient survival following SPK transplant was 85% in Era 2, compared to 92% in Eras 3 and 4 combined. Graft survival was 64% and 79%, respectively.

In Era 1, patient and graft survival rates, following PAK transplants, were 86% and 17%, respectively. In Era 4 these figures were 98% and 81%.

PTA transplant patient and survival rates were 77% and 31%, and 100% and 88%, for Eras 1 and 4 respectively.

SPK graft survival rates were significantly higher with bladder drainage (82%) than enteric drainage (74%) at 1 year.

Increasing recipient age had an adverse effect on outcome only in SPK recipients. Vascular disease was found to be common; those with no vascular disease had significantly higher patient and graft survival rates in the SPK and PAK categories.

Living donor segmental pancreas transplants were associated with higher technically successful graft survival rates in each era.

The researchers found that pancreatic transplants reduced diabetic secondary complications in some recipients. Quality of life was improved in all patients.

Dr David Sutherland, of the University of Minnesota, said on behalf of the group, "Patient and graft survival rates have significantly improved over time as surgical techniques and immunosuppressive protocols have evolved.

"Eventually, islet transplants will replace pancreas transplants for suitable candidates, but currently pancreas transplants can be applied, and should be an option at all stages of diabetes. Early transplants are preferable for labile diabetes, but even patients with advanced complications can benefit," he concluded.

Ann Surg 2001; 233: 463-501
09 May 2001

Go to top of page Email this page Email this page to a colleague

 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us